Neos Therapeutics Inc (NEOS) Given Consensus Rating of “Hold” by Brokerages

Shares of Neos Therapeutics Inc (NASDAQ:NEOS) have been assigned an average rating of “Hold” from the eight brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $15.33.

Several equities research analysts have recently commented on the company. ValuEngine upgraded Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. BidaskClub upgraded Neos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, March 10th. Cantor Fitzgerald set a $20.00 price objective on Neos Therapeutics and gave the company a “buy” rating in a report on Thursday, March 15th. Wells Fargo & Co set a $14.00 price objective on Neos Therapeutics and gave the company a “buy” rating in a report on Saturday, March 17th. Finally, Zacks Investment Research upgraded Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, March 22nd.

Institutional investors have recently made changes to their positions in the stock. Paloma Partners Management Co bought a new stake in Neos Therapeutics during the fourth quarter worth $125,000. MetLife Investment Advisors LLC bought a new stake in Neos Therapeutics during the fourth quarter worth $134,000. Quantitative Systematic Strategies LLC bought a new stake in Neos Therapeutics during the first quarter worth $123,000. Brandywine Global Investment Management LLC bought a new stake in Neos Therapeutics during the fourth quarter worth $179,000. Finally, Allianz Asset Management GmbH bought a new stake in Neos Therapeutics during the first quarter worth $161,000. Institutional investors and hedge funds own 52.51% of the company’s stock.

Neos Therapeutics opened at $6.60 on Thursday, according to MarketBeat. The company has a market cap of $192.83 million, a PE ratio of -2.46 and a beta of -0.29. Neos Therapeutics has a 52 week low of $6.04 and a 52 week high of $13.15. The company has a quick ratio of 1.49, a current ratio of 1.82 and a debt-to-equity ratio of -13.08.

Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings data on Wednesday, May 9th. The company reported ($0.50) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.02). The firm had revenue of $10.73 million for the quarter. Neos Therapeutics had a negative net margin of 211.13% and a negative return on equity of 586.25%. equities analysts anticipate that Neos Therapeutics will post -1.5 earnings per share for the current fiscal year.

About Neos Therapeutics

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Analyst Recommendations for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply